Founding CEO of five biotechnology companies—including 3 IPOs, 3 trade-sales, 3 companies gaining market capitalizations of over $2 billion: Infinitek, producer of Biomek, acquired by SmithKline Beckman (1984), Oxford GlycoSciences (IPO 1988), Orchid Biosciences (IPO 2000), Acuity Pharmaceuticals (now OPKO Health, 2007), Receptor Biologix (sold 2009), NuMe Health (founded 2009, now MBT). Currently is the US-based General Partner of the London-based Advent Life Sciences—a venture capital group focused entirely on investing in the US and Europe in the life sciences. Dale is able to commit 50% of his time with MBT.
20+ years at Eli Lilly, served as CSO of obesity drug discovery, inventor of successful drug Lanreotide, author of 100+ papers, helped develop 30 drug-related patents, Fellow of Obesity Society and serves on the editorial board of Current Medicinal Chemistry-Immunology Endocrinology and Metabolic Agents in Medicinal Chemistry and Molecular Metabolism. Recognized leader in the emerging science of the microbiome. Inventor on the patents of MBT. Mark is a full time employee of MBT.
Emeritus Exec Director of Levy Rosenblum Institute, 2013 Tulane Distinguished Entrepreneur and Social Entrepreneur of the Year, Chairman of Whole Foods Market, first CFO of Celestial Seasonings, Board member of multiple successful health food and supplement companies: Traditional Medicinals, Sambazon, WhiteWave Foods (Silk Soy Milk). He was named the Ernst and Young Louisiana Entrepreneur of the Year in 1997 and in 2007 he was awarded the Howard W. Wissner Award in recognition of excellence in teaching, interest in students and their activities and exceptional efforts to improve the A. B. Freeman School of Business.